inclusion criteria: 1. subjects are fully aware of the purpose, nature, methods and possible adverse reactions of the study, voluntarily serve as subjects, and sign the informed consent form before the start of any study procedures, and ensure that he/she will participate in any procedures in the study in person; 2. subjects are able to communicate well with the investigator and understand and comply with the requirements of the study; 3. the subject has no history of chronic or serious diseases involving the cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immune, psychiatric, neurological, gastrointestinal system, and has a good general health condition; 4. subjects (including male subjects) do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and shall voluntarily take non-pharmaceutical contraception measures during the trial period; 5. male or female subjects aged 18 to 45 years (including 18 and 45 years); 6. weight ≥ 50.0 kg for males, or weight ≥ 45.0 kg for females, and body mass index (bmi) in the range of 19.0 \~ 26.0 kg/m2 (including cut-off value); 7. vital signs, physical examination, clinical laboratory tests (hematology, urinalysis, blood biochemistry, blood transfusion, coagulation function, pregnancy test \[female\], alcohol and drug screening, etc.), 12-lead electrocardiogram, chest x-ray and abdominal b-ultrasonography show no abnormalities or abnormalities without clinical significance.

inclusion criteria: 1. subjects are fully aware of the purpose, nature, methods and possible adverse reactions of the study, voluntarily serve as subjects, and sign the informed consent form before the start of any study procedures, and ensure that he/she will participate in any procedures in the study in person; 2. subjects are able to communicate well with the investigator and understand and comply with the requirements of the study; 3. the subject has no history of chronic or serious diseases involving the cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immune, psychiatric, neurological, gastrointestinal system, and has a good general health condition; 4. subjects (including male subjects) do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and shall voluntarily take non-pharmaceutical contraception measures during the trial period; 5. male or female subjects aged 18 to 45 years (including 18 and 45 years); 6. weight ≥ 50.0 kg for males, or weight ≥ 45.0 kg for females, and body mass index (bmi) in the range of 19.0 \~ 26.0 kg/m2 (including cut-off value); 7. vital signs, physical examination, clinical laboratory tests (hematology, urinalysis, blood biochemistry, blood transfusion, coagulation function, pregnancy test \[female\], alcohol and drug screening, etc.), 12-lead electrocardiogram, chest x-ray and abdominal b-ultrasonography show no abnormalities or abnormalities without clinical significance.

inclusion criteria: subjects are fully aware of the purpose, nature, methods and possible adverse reactions of the study, voluntarily serve as subjects, and sign the informed consent form before the start of any study procedures, and ensure that he/she will participate in any procedures in the study in person; subjects are able to communicate well with the investigator and understand and comply with the requirements of the study; the subject has no history of chronic or serious diseases involving the cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immune, psychiatric, neurological, gastrointestinal system, and has a good general health condition; subjects (including male subjects) do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and shall voluntarily take non-pharmaceutical contraception measures during the trial period; male or female subjects aged 18 to 45 years (including 18 and 45 years); weight ≥ 50.0 kg for males, or weight ≥ 45.0 kg for females, and body mass index (bmi) in the range of 19.0 ~ 26.0 kg/m2 (including cut-off value); vital signs, physical examination, clinical laboratory tests (hematology, urinalysis, blood biochemistry, blood transfusion, coagulation function, pregnancy test [female], alcohol and drug screening, etc.), 12-lead electrocardiogram, chest x-ray and abdominal b-ultrasonography show no abnormalities or abnormalities without clinical significance.

inclusion criteria: subjects are fully aware of the purpose, nature, methods and possible adverse reactions of the study, voluntarily serve as subjects, and sign the informed consent form before the start of any study procedures, and ensure that he/she will participate in any procedures in the study in person; subjects are able to communicate well with the investigator and understand and comply with the requirements of the study; the subject has no history of chronic or serious diseases involving the cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immune, psychiatric, neurological, gastrointestinal system, and has a good general health condition; subjects (including male subjects) do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and shall voluntarily take non-pharmaceutical contraception measures during the trial period; male or female subjects aged 18 to 45 years (including 18 and 45 years); weight ≥ 50.0 kg for males, or weight ≥ 45.0 kg for females, and body mass index (bmi) in the range of 19.0 ~ 26.0 kg/m2 (including cut-off value); vital signs, physical examination, clinical laboratory tests (hematology, urinalysis, blood biochemistry, blood transfusion, coagulation function, pregnancy test [female], alcohol and drug screening, etc.), 12-lead electrocardiogram, chest x-ray and abdominal b-ultrasonography show no abnormalities or abnormalities without clinical significance.

inclusion criteria: 1. subjects are fully aware of the purpose, nature, methods and possible adverse reactions of the study, voluntarily serve as subjects, and sign the informed consent form before the start of any study procedures, and ensure that he/she will participate in any procedures in the study in person; 2. subjects are able to communicate well with the investigator and understand and comply with the requirements of the study; 3. the subject has no history of chronic or serious diseases involving the cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immune, psychiatric, neurological, gastrointestinal system, and has a good general health condition; 4. subjects (including male subjects) do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and shall voluntarily take non-pharmaceutical contraception measures during the trial period; 5. male or female subjects aged 18 to 45 years (including 18 and 45 years); 6. weight ≥ 50.0 kg for males, or weight ≥ 45.0 kg for females, and body mass index (bmi) in the range of 19.0 ~ 26.0 kg/m2 (including cut-off value); 7. vital signs, physical examination, clinical laboratory tests (hematology, urinalysis, blood biochemistry, blood transfusion, coagulation function, pregnancy test [female], alcohol and drug screening, etc.), 12-lead electrocardiogram, chest x-ray and abdominal b-ultrasonography show no abnormalities or abnormalities without clinical significance.

inclusion criteria: 1. subjects are fully aware of the purpose, nature, methods and possible adverse reactions of the study, voluntarily serve as subjects, and sign the informed consent form before the start of any study procedures, and ensure that he/she will participate in any procedures in the study in person; 2. subjects are able to communicate well with the investigator and understand and comply with the requirements of the study; 3. the subject has no history of chronic or serious diseases involving the cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immune, psychiatric, neurological, gastrointestinal system, and has a good general health condition; 4. subjects (including male subjects) do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and shall voluntarily take non-pharmaceutical contraception measures during the trial period; 5. male or female subjects aged 18 to 45 years (including 18 and 45 years); 6. weight ≥ 50.0 kg for males, or weight ≥ 45.0 kg for females, and body mass index (bmi) in the range of 19.0 ~ 26.0 kg/m2 (including cut-off value); 7. vital signs, physical examination, clinical laboratory tests (hematology, urinalysis, blood biochemistry, blood transfusion, coagulation function, pregnancy test [female], alcohol and drug screening, etc.), 12-lead electrocardiogram, chest x-ray and abdominal b-ultrasonography show no abnormalities or abnormalities without clinical significance.